Several early clinical trials utilizing unmodified naked tumor-antigen mRNA vaccines demonstrated their feasibility and safety, inducing antigen-specific CD4+ and CD8 + T-cell responses [293, 294]. The gene discussed is CD8A; the disease is neoplasm.